


PHARMACEUTICAL 2022

PROCYON CORP Rank 17 of 475







RealRate

PHARMACEUTICAL 2022

PROCYON CORP Rank 17 of 475

The relative strengths and weaknesses of PROCYON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROCYON CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 752% points. The greatest weakness of PROCYON CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 176% points.

The company's Economic Capital Ratio, given in the ranking table, is 230%, being 506% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	2,872
Cost of Goods Sold	1,331
Intangible Assets	17
Liabilities, Current	637
Liabilities, Non-Current	654
Other Assets	1,244
Other Compr. Net Income	0
Other Expenses	1,798
Other Liabilities	0
Other Net Income	507
Property and Equipment	109
Research and Development	0
Revenues	4,720
Selling, General and Administrative Expense	1,330

Output Variable	Value in 1000 USD
Assets	4,242
Liabilities	1,291
Expenses	4,459
Stockholders Equity	2,951
Net Income	768
Comprehensive Net Income	768
Economic Capital Ratio	230%

